Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 6Phase NA 3Phase 1 3Phase 4 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 4Immunoglobulin Light-chain Amyloidosis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Waldenstrom Macroglobulinemia 1Plasmacytoma 1Noninsulin-dependent diabetes mellitus with deafness 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Burkitt Lymphoma 1Amyloidosis 1

Interventions

Dexamethasone 4Whole-Body Irradiation 3Bortezomib 3pomalidomide 2fludarabine phosphate 2daratumumab 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Cyclosporine 2Cyclophosphamide 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2venetoclax 1darlin protein, Dictyostelium 1Thiotepa 1Oxycodone 1Music Therapy 1Moxifloxacin 1Morphine 1Methadone 1Melphalan 1Massage 1Hyaluronoglucosaminidase 1Focal Adhesion Protein-Tyrosine Kinases 1Fluorescent Antibody Technique 1Etoposide 1Doxycycline 1Ciprofloxacin 1Carmustine 1Carboplatin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × Immunoglobulin Light-chain Amyloidosis × Bortezomib × Clear all
NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Peking University People's Hospital

Phase NA Recruiting
41 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03401372 2021-02-23

BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

Peking Union Medical College Hospital

Phase NA Completed
140 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT01383759 2020-04-07

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Memorial Sloan Kettering Cancer Center

Phase NA Completed
20 enrolled 16 charts
Plasma cell

Noninsulin-dependent diabetes mellitus with deafness, Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡